Evidence map›Paper›PMID 35697709›Full record

ArticleNPJ Parkinson's disease2022

Effects of MAO-B inhibitors on non-motor symptoms and quality of life in Parkinson's disease: A systematic review.

Takashi Tsuboi, Yuki Satake, Keita Hiraga, Katsunori Yokoi, Makoto Hattori, Masashi Suzuki, Kazuhiro Hara, Adolfo Ramirez-Zamora, Michael S Okun, Masahisa Katsuno

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ Parkinson's disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 5 pooled it
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 5 syntheses or guidelines pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Phytochemical Characterization ofMolecules (Basel, Switzerland) · 2026
    Article
  8. Article
  9. Novel Insights on Benzo[Antioxidants (Basel, Switzerland) · 2026
    Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Pharmaceuticals (Basel, Switzerland) · 2024
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Takashi TsuboiDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID http://orcid.org/0000-0001-5042-3181
Yuki SatakeDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Keita HiragaDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID http://orcid.org/0000-0002-0134-2956
Katsunori YokoiDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Makoto HattoriDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Masashi SuzukiDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Kazuhiro HaraDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Adolfo Ramirez-ZamoraDepartment of Neurology, Norman Fixel Institute for Neurological Diseases, University of Florida, Gainesville, FL, USA.
Michael S OkunDepartment of Neurology, Norman Fixel Institute for Neurological Diseases, University of Florida, Gainesville, FL, USA.ORCID http://orcid.org/0000-0002-6247-9358
Masahisa KatsunoDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan. ka2no@med.nagoya-u.ac.jp.ORCID http://orcid.org/0000-0001-9453-9311
Nagoya University · JPUniversity of Florida · USNagoya University Hospital · JPNational Center for Geriatrics and Gerontology · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-motor symptoms (NMS) are common among patients with Parkinson's disease and reduce patients' quality of life (QOL). However, there remain considerable unmet needs for NMS management. Three monoamine oxidase B inhibitors (MAO-BIs), selegiline, rasagiline, and safinamide, have become commercially available in many countries. Although an increasing number of studies have reported potential beneficial effects of MAO-BIs on QOL and NMS, there has been no consensus. Thus, the primary objective of this study was to provide an up-to-date systematic review of the QOL and NMS outcomes from the available clinical studies of MAO-BIs. We conducted a literature search using the PubMed, Scopus, and Cochrane Library databases in November 2021. We identified 60 publications relevant to this topic. Overall, rasagiline and safinamide had more published evidence on QOL and NMS changes compared with selegiline. This was likely impacted by selegiline being introduced many years prior to the field embarking on the study of NMS. The impact of MAO-BIs on QOL was inconsistent across studies, and this was unlikely to be clinically meaningful. MAO-BIs may potentially improve depression, sleep disturbances, and pain. In contrast, cognitive and olfactory dysfunctions are likely unresponsive to MAO-BIs. Given the paucity of evidence and controlled, long-term studies, the effects of MAO-BIs on fatigue, autonomic dysfunctions, apathy, and ICD remain unclear. The effects of MAO-BIs on static and fluctuating NMS have never been investigated systematically. More high-quality studies will be needed and should enable clinicians to provide personalized medicine based on a non-motor symptom profile.

Identifiers

PMID35697709
PMCPMC9192747
OpenAlexW4282555670

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.